Activation of muscarinic receptors inhibits glutamate-induced GSK-3β overactivation in PC12 cells

Acta Pharmacologica Sinica

Volumn 34, Issue 7, 2013, Pages 886-892

  Ma, Ke ^a   Yang, Li Min ^a   Chen, Hong Zhuan ^a   Lu, Yang ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Alzheimer's disease; carbachol; excitotoxicity; glutamate; GSK 3I; I catenin; muscarinic receptors; neuroprotection; PC12 cell

Indexed keywords

BETA CATENIN; CARBACHOL; GLUTAMIC ACID; GLYCOGEN SYNTHASE KINASE 3BETA; LUCIFERASE; MUSCARINIC RECEPTOR;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL DEATH; CELL VIABILITY; CONCENTRATION (PARAMETERS); GENE ACTIVATION; GENE EXPRESSION; GENE TRANSLOCATION; IMMUNOFLUORESCENCE; NEUROTOXICITY; NONHUMAN; PC12 CELL; RAT; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; GLUTAMIC ACID; GLYCOGEN SYNTHASE KINASE 3; PC12 CELLS; RATS; RECEPTORS, MUSCARINIC;

EID: 84881455718     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2013.42     Document Type: Article

References (41)

1. Shah RS, Lee HG, Xiongwei Z, Perry G, Smith MA, Castellani RJ. Current approaches in the treatment of Alzheimer's disease. Biomed Pharmacother 2008; 62: 199-207.
2. Ladner CJ, Lee JM. Pharmacological drug treatment of Alzheimer disease: the cholinergic hypothesis revisited. J Neuropathol Exp Neurol 1998; 5: 719-31.
3. Fisher A. Therapeutic strategies in Alzheimer's disease: M1 muscarinic agonists. Jpn J Pharmacol 2000; 84: 101-12.
4. Longo FM, Massa SM. Neuroprotective strategies in Alzheimer's disease. NeuroRx 2004; 1: 117-27.
5. Caccamo A, Fisher A, LaFerla FM. M1 agonists as a potential diseasemodifying therapy for Alzheimer's disease. Curr Alzheimer Res 2009; 6: 112-7.
6. Tobin AB, Budd DC. The anti-Apoptotic response of the Gq/11-coupled muscarinic receptor family. Biochem Soc Trans 2003; 31: 1182-5.
7. Farias GG, Godoy JA, Hernandez F, Avila J, Fisher A, Inestrosa NC. M1 muscarinic receptor activation protects neurons from beta-Amyloid toxicity. A role for Wnt signaling pathway. Neurobiol Dis 2004; 17: 337-48.
8. De Sarno P, Shestopal SA, King TD, Zmijewska A, Song L, Jope RS. Muscarinic receptor activation protects cells from apoptotic effects of DNA damage, oxidative stress, and mitochondrial inhibition. J Biol Chem 2003; 278: 11086-93.
9. Lindenboim L, Pinkas-Kramarski R, Sokolovsky M, Stein R. Activation of muscarinic receptors inhibits apoptosis in PC12M1 cells. J Neurochem 1995; 64: 2491-9.
10. Choi DW. Glutamate neurotoxicity and diseases of the nervous system. Neuron 1988; 1: 623-34.
11. Olney JW. Excitotoxicity: an overview. Can Dis Wkly Rep 1990; 16: 47-57.
12. Doble A. The role of excitotoxicity in neurodegenerative disease: implications for therapy. Pharmacol Ther 1999; 81: 163-221.
13. Dong XX, Wang Y, Qin ZH. Molecular mechanisms of excitotoxicity and their relevance to pathogenesis of neurodegenerative diseases. Acta Pharmacol Sin 2009; 30: 379-87.
14. Lau A, Tymianski M. Glutamate receptors, neurotoxicity and neurodegeneration. Pflugers Arch 2010; 460: 525-42.
15. Guan ZZ. Cross-talk between oxidative stress and modifications of cholinergic and glutaminergic receptors in the pathogenesis of Alzheimer's disease. Acta Pharmacol Sin 2008; 29: 773-80.
16. Dale TC. Signal transduction by the Wnt family of ligands. Biochem J 1998; 329: 209-23.
17. Rubinfeld B, Albert I, Porfiri E, Fiol C, Munemitsu S, Polakis P. Binding of GSK3beta to the APC-beta-catenin complex and regulation of complex assembly. Science 1996; 272: 1023-6.
18. Frame S, Cohen P. GSK3 takes centre stage more than 20 years after its discovery. Biochem J 2001; 359: 1-16.
19. Carmichael J, Sugars KL, Bao YP, Rubinsztein DC. Glycogen synthase kinase-3beta inhibitors prevent cellular polyglutamine toxicity caused by the Huntington's disease mutation. J Biol Chem 2002; 277: 33791-8.
20. Maggirwar SB, Tong N, Ramirez S, Gelbard HA, Dewhurst S. HIV-1 Tatmediated activation of glycogen synthase kinase-3beta contributes to Tat-mediated neurotoxicity. J Neurochem 1999; 73: 578-86.
21. Pap M, Cooper GM. Role of glycogen synthase kinase-3 in the phosphatidylinositol 3-Kinase/Akt cell survival pathway. J Biol Chem 1998; 273: 19929-32.
22. Tong N, Sanchez JF, Maggirwar SB, Ramirez SH, Guo H, Dewhurst S, et al. Activation of glycogen synthase kinase 3 beta (GSK-3beta) by platelet activating factor mediates migration and cell death in cerebellar granule neurons. Eur J Neurosci 2001; 13: 1913-22.
23. Jacobs KM, Bhave SR, Ferraro DJ, Jaboin JJ, Hallahan DE, Thotala D. GSK-3beta: a bifunctional role in cell death pathways. Int J Cell Biol 2012; 2012: 930710.
24. Forlenza OV, Spink JM, Dayanandan R, Anderton BH, Olesen OF, Lovestone S. Muscarinic agonists reduce tau phosphorylation in nonneuronal cells via GSK-3beta inhibition and in neurons. J Neural Transm 2000; 107: 1201-12.
25. del Ser T, Steinwachs KC, Gertz HJ, Andres MV, Gomez-Carrillo B, Medina M, et al. Treatment of Alzheimer's disease with the GSK-3 inhibitor tideglusib: a pilot study. J Alzheimers Dis 2013; 33: 205-15.
26. Fisher A. M1 muscarinic agonists target major hallmarks of Alzheimer's disease - an update. Curr Alzheimer Res 2007; 4: 577-80.
27. Martinez A, Alonso M, Castro A, Perez C, Moreno FJ. First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease. J Med Chem 2002; 45: 1292-9.
28. Goode N, Hughes K, Woodgett JR, Parker PJ. Differential regulation of glycogen synthase kinase-3 beta by protein kinase C isotypes. J Biol Chem 1992; 267: 16878-82.
29. Shaw M, Cohen P, Alessi DR. Further evidence that the inhibition of glycogen synthase kinase-3beta by IGF-1 is mediated by PDK1/PKBinduced phosphorylation of Ser-9 and not by dephosphorylation of Tyr-216. FEBS Lett 1997; 416: 307-11.
30. Patapoutian A, Reichardt LF. Roles of Wnt proteins in neural development and maintenance. Curr Opin Neurobiol 2000; 10: 392-9.
31. Eldar-Finkelman H. Glycogen synthase kinase 3: an emerging therapeutic target. Trends Mol Med 2002; 8: 126-32.
32. Sereno L, Coma M, Rodriguez M, Sanchez-Ferrer P, Sanchez MB, Gich I, et al. A novel GSK-3beta inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo. Neurobiol Dis 2009; 35: 359-67.
33. Froissard P, Duval D. Cytotoxic effects of glutamic acid on PC12 cells. Neurochem Int 1994; 24: 485-93.
34. Lee JH, Lee EO, Kang JL, Chong YH. Concomitant degradation of betacatenin and GSK-3 beta potently contributes to glutamate-induced neurotoxicity in rat hippocampal slice cultures. J Neurochem 2008; 106: 1066-77.
35. Bhat RV, Shanley J, Correll MP, Fieles WE, Keith RA, Scott CW, et al. Regulation and localization of tyrosine216 phosphorylation of glycogen synthase kinase-3beta in cellular and animal models of neuronal degeneration. Proc Natl Acad Sci U S A 2000; 97: 11074-9.
36. Hetman M, Cavanaugh JE, Kimelman D, Xia Z. Role of glycogen synthase kinase-3beta in neuronal apoptosis induced by trophic withdrawal. J Neurosci 2000; 20: 2567-74.
37. Crowder RJ, Freeman RS. Glycogen synthase kinase-3 beta activity is critical for neuronal death caused by inhibiting phosphatidylinositol 3-kinase or Akt but not for death caused by nerve growth factor withdrawal. J Biol Chem 2000; 275: 34266-71.
38. Hart MJ, de los Santos R, Albert IN, Rubinfeld B, Polakis P. Downregulation of beta-catenin by human Axin and its association with the APC tumor suppressor, beta-catenin and GSK3 beta. Curr Biol 1998; 8: 573-81.
39. Li HL, Wang HH, Liu SJ, Deng YQ, Zhang YJ, Tian Q, et al. Phosphorylation of tau antagonizes apoptosis by stabilizing beta-catenin, a mechanism involved in Alzheimer's neurodegeneration. Proc Natl Acad Sci U S A 2007; 104: 3591-6.
40. Giese KP. GSK-3: a key player in neurodegeneration and memory. IUBMB Life 2009; 61: 516-21.
41. Medina M, Avila J. Glycogen synthase kinase-3 (GSK-3) inhibitors for the treatment of Alzheimer's disease. Curr Pharm Des 2010; 16: 2790-8.